Shengliang Zhang

The paper identifies small molecules that induce apoptosis in BRCA1-deficient cancer cells and links PPAR beta/delta inhibition to poor survival in breast cancer patients.

This study shows TTFields increase p21 expression and induce cell death in TNBC cells, with enhanced effects when combined with talazoparib.

This paper shows that combining prexasertib with lurbinectedin synergistically kills small cell lung cancer cells by disrupting G2/M checkpoint responses.

This paper shows that combining ONC201 or ONC206 with temozolomide and radiotherapy significantly extends survival in a GBM mouse model compared to single treatments.

This study shows that ONC201 is effective against prostate cancer and small cell lung carcinoma cells, regardless of neuroendocrine differentiation markers or BRN2 overexpression.

This study shows p73 upregulates c-FLIP to suppress extrinsic apoptosis, and a compound degrades c-FLIP to enhance p73's antitumor effects in p53-mutant cancers.

This study shows that inhibiting ITGB6 enhances anti-tumor immune responses in mouse models of head and neck and pancreatic cancers, with potential for combination immunotherapy.

This study shows that SARS-CoV-2 spike S2 subunit inhibits p53 activation of p21(WAF1), DR5, and MDM2 in cancer cells, potentially affecting tumorigenesis and chemotherapy response.

This study investigates how senescent fibroblasts influence tumor growth and immune response, showing that targeting the p21-driven SASP and combining senolytics with cancer therapies can suppress tumor growth.